DiaMedica Therapeutics Inc. (DMAC)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $7.82
- As of
Kresmion compiles this page from DMAC's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
DiaMedica Therapeutics Inc. (DMAC): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-10.
See the full DMAC dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for DMAC on one page. Preview it with sample data, then open it live with a free account.
Preview the DMAC dossierActive signals for DMAC
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 6.9%, EPS $-0.19 vs $-0.204 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1031% to DMAC (2026Q2)
- mediumNEW_POSITION
RENAISSANCE TECHNOLOGIES LLC new position in DMAC
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 7.1% - EPS $-0.18 vs $-0.1938 estimate
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 7.4% - EPS $-0.17 vs $-0.1836 estimate
FREE, NO ACCOUNT
Every signal on DMAC, as it fires
New filings, 13F moves and cross asset signals on DMAC land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in DMAC (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 25253X207 · 2026Q2 | $6M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 25253X207 · 2026Q2 | $1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, DMAC
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
DMAC against its peers
DMAC's return on equity of -58.4% ranks in the 64th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | DMAC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 40.5M | n/a | 13 |
| Operating margin | n/a | -358.9% | n/a | 11 |
| Net margin | n/a | -240.1% | n/a | 11 |
| Return on equity | -58.4% | -68.2% | 64 | 17 |
| 1 year | 10.8% | -16.7% | 72 | 15 |
Peers (20): YDES, PRTA, ENTX, ZURA, TECX, SPRY, CAPR, AUTL, RZLT, MYGN, EPRX, KYTX, ASMB, OVID, AGEN, EDIT, RLMD, ARVN, GALT, TTRX. Left out: PRTC (period gap), AGMB (no annual filing), EIKN (no annual filing), TRXB (no annual filing), SCTX (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (DMAC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow DMAC on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to DMAC for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.